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y 28, 2013.he aim of this study was to characterize a single-center experience of major bleeding complications during
HeartMate II (HMII) (Thoratec Corp., Pleasanton, California) left ventricular assist device support, with focus on the
subtypes and temporal patterns of post-operative bleeding.Background Bleeding complications are the most common post-operative adverse events after HMII implantation. The timing of
bleeding events, relationship to coagulation status, and effect on post-operative survival are incompletely
understood.Methods From October 2004 to June 2010, 139 HMII recipients at the Cleveland Clinic received 145 devices as a bridge to
transplant or destination therapy for advanced heart failure. Major bleeding was deﬁned using Interagency Registry
for Mechanically Assisted Circulatory Support criteria, with an additional category created to maximize sensitivity for
events. Pre-operative variables, coagulation status, and bleeding recurrence were assessed for correlation to primary
events using modulated renewal within a multivariable analysis.Results The cumulative occurrence of major bleeding was 58% during 171 patient-years of follow-up. There were 1.14 major
bleeds per patient-year, with 44% occurring as repeat bleeding events. A ﬁrst bleed did not predict subsequent
bleeding. The greatest risk of bleeding was noted within 2 weeks post-implantation. The international normalized
ratio proﬁle correlated poorly with the risk of bleeding. Bleeding early after surgery was associated with reduced
survival while on HMII support.Conclusions The risk of bleeding peaks early after HMII implantation. Bleeding of thoracic and gastrointestinal sources dominates
these events, although many patients undergo transfusions for anemia without an apparent source of hemolysis or
bleeding. (J Am Coll Cardiol 2013;62:2188–96) ª 2013 by the American College of Cardiology FoundationDespite advances in mechanical circulatory support, bleeding
remains the most common adverse event after implantation
of the HeartMate II (HMII) (Thoratec Corp., Pleasanton,
California) ventricular assist device (1–4). Post-implantation
bleeding complications diminish the overall effectiveness of
HMII in treating advanced heart failure as a bridge to
transplant (BTT) (5). Transfusion-related bleeding repre-
sents a decidedly ominous problem; the deleterious effect of
red blood cell transfusion on HMII recipient survival has
been well described (6,7). With growing use of the HMII as
destination therapy, bleeding rates among this population
are comparatively higher (3) relative to cohorts who receivescular Medicine, Cleveland Clinic, Cleveland,
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013; revised manuscript received April 7, 2013,an implant as a BTT (2). Therefore, efforts to reduce the
rate of bleeding are imperative and urgently needed.
See page 2197
Bleeding complications are complex and dynamic
phenomena that are likely dependent on many pre-operative
and post-operative factors (5,6,8). From our clinical expe-
rience, some HMII recipients experience numerous bleeding
events, whereas many others have none at all. Available
reports that characterize HMII-related bleeding are often
limited by variable bleeding deﬁnitions across studies,
restricted characterization of bleeding subtypes, and het-
erogeneous inclusion of non-HMII devices. Accordingly,
broad conclusions about post-HMII bleeding have been
challenged by variability in post-operative management
over time and across centers. Currently available HMII
registries offer insufﬁcient detail to account for features of
bleeding complications. Whether the temporal patterns of
bleeding, sources of blood loss, and impact of recurrent
Abbreviations
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2189bleeding contribute to future events is not well understood.
Therefore, we performed a detailed examination of post-
HMII bleeding to address these limitations while pro-
viding novel insights that might direct future HMII care.
The aims of this study were to: 1) characterize the timing
and subtypes of post-operative major bleeding after HMII
implantation using standardized Interagency Registry for
Mechanically Assisted Circulatory Support (INTERMACS)
deﬁnitions for these events while using time-sensitive
modeling techniques; 2) determine the inﬂuence of coagula-
tion status on subsequent risks for bleeding; and 3) assess the
association of bleeding events on post-surgical mortality.Methods
Study population. From October 2004 to June 2010,
145 consecutive patients older than 18 years of age received
a HMII device at the Cleveland Clinic. To limit potential
confounding, patients who received other forms of pre- or
post-operative mechanical circulatory support (e.g.,
concomitant right ventricular support device, prior pulsatile
ventricular assist device, or prior biventricular support
device) (n ¼ 6) were not included in this analysis. Those
receiving pre-operative intra-aortic balloon counterpulsation
or extracorporeal membrane oxygenation were not excluded.
The resulting 139 patients received 145 HMII implants,
including 6 HMII reimplants. After institutional review
board approval, patient characteristics, details of HMII
implantation, and post-operative data were retrieved from
prospectively populated institutional databases approved for
research with patient consent waived.
Patients were followed up until transplantation, death, or
a study completion date that allowed for at least 3 months
of follow-up. Primary bleeding events were deﬁned using
INTERMACS adverse event criteria whenever possible (9).
Because we encountered numerous major anemia events
without a determined source of bleeding or hemolysis, a
unique category of bleeding was created to maximize sensi-
tivity for all events leading to transfusion (see “primary event
deﬁnitions”). All primary bleeding outcomes were adjudicated
against medical records applying these deﬁnitions.
Values for pre-operative variables were recorded nearest
to the date of surgery and within 14 days of HMII
implantation. Details of bleeding complications and medi-
cation use were retrospectively collected from chart review
and input into an institutionally-licensed Research Elec-
tronic Data Capture online database (Vanderbilt University,
Nashville, Tennessee) (10) hosted at the Cleveland Clinic
and then merged with existing prospectively populated
information from an institutional database for ﬁnal analysis.
Institutional anticoagulation protocol. Like many
centers, our initial HMII experience began with com-
paratively aggressive post-operative anticoagulation held
over from an era of implanting pulsatile mechanical cir-
culatory support devices. From our ﬁrst HMII implant in
2004 to early 2008, most patients with implants receivedan anticoagluation regimen of
aspirin 325 mg daily plus upfront
heparin infusion with a bridge to
warfarin. Warfarin was admin-
istered to a target international
normalized ratio (INR) of 2.0
to 3.0 with subsequent dis-
continuation of heparin. High
rates of post-operative bleeding
coupled with emerging evidence
of a low risk of early post-operative pump thrombosis (11)
led to a more conservative anticoagulation protocol, essen-
tially eliminating early post-operative heparin use. By mid-
2008, heparin was no longer used routinely to bridge to
a therapeutic INR. Initiation of warfarin was generally
delayed until 1 to 2 weeks after surgery and administered to
a more conservative goal INR of 1.7 to 2.5. The dose of
aspirin was also adjusted to include doses of 81 to 325 mg
daily. Figure 1 illustrates the timing of bleeding complica-
tions relative to time of surgery, heparin use, and initiation
of warfarin among our 139 patients.
Primary event deﬁnitions. We sought high sensitivity for
bleeding events that resulted in transfusion. INTERMACS
adverse event deﬁnitions were used for primary events,
including transfusion criteria of 4 U of red blood cells in
the ﬁrst post-operative week or any transfusion associated
with bleeding thereafter (Online Appendix).
All bleeding was subtyped while satisfying time-sensitive
INTERMACS transfusion criteria based on temporal
distance from surgery. Thoracic and mediastinal bleeding
was deﬁned as bleeding that met transfusion requirements
and required return to the operating room for surgical
exploration or was associated with a clinically conﬁrmed
source of thoracic bleeding not managed surgically. Gas-
trointestinal (GI) bleeding was deﬁned as bleeding that met
transfusion requirements and was associated with a con-
ﬁrmed upper or lower source of bleeding. Hemorrhagic
stroke was considered a major bleeding event, although it is
technically listed as a central nervous system event under
INTERMACS adverse event criteria. Other bleeding
subtypes and cases of hemolysis were categorized separately.
When a clinically signiﬁcant nonhemolytic anemia
met INTERMACS transfusion criteria but a bleeding
source could not be identiﬁed despite invasive or noninvasive
testing, the event was classiﬁed as anemia of undetermined
source (AUS). We considered AUS events important
to capture given the reported association between trans-
fusion and post-operative mortality, although they are not
accounted for by INTERMACS adverse event criteria (6,7).
Statistical analysis. All data were analyzed using SAS
software (SAS Institute, Inc., Cary, North Carolina).
Continuous data in tables are summarized as mean  SD.
Continuous data in ﬁgures are reported as mean with cor-
responding 68% conﬁdence intervals equivalent to 1 SE.
Categorical data are summarized as percentages. Nelson’s
cumulative event function provided nonparametric estimates
Figure 1 Anticoagulation and Bleeding Events in the First 31 Days After HMII Implantation
Bleeding events (red squares) are indicated along with initiation of heparin (blue circles) and warfarin (green triangles) among 139 cumulative patients with HMII implants from
2004 to 2010. Each solid line represents 1 patient with follow-up through 31 days. Dashed lines represent censored patients. HMII ¼ HeartMate II. Censoring event type:
D ¼ death; T ¼ transplant; R ¼ right ventricular assist device.
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2190of bleeding prevalence (12). Parametric estimates were ob-
tained by multivariable hazard phase methodology to esti-
mate the instantaneous risk of bleeding relative to temporal
distance from HMII implantation (13). See the Online
Appendix for a full list of demographic and clinical vari-
ables used.
Bleeding events after HMII implantation were modeled
as repeated occurrences to determine an effect of prior
bleeding on future events. Modulated renewal was used in
a multivariable analysis such that primary bleeding outcomeevents were modeled as time-varying covariates, similar to
techniques previously described (13). Applying this meth-
odology, a patient who experienced a primary event was
restarted in the model at time zero and followed up for
occurrence of subsequent events (14). To this end, our
model not only considered pre-operative covariates but also
the timing and nonlinear effects of transient risk factors,
such as a prior bleed, to predict subsequent events.
Risk factors for post-implantation bleeding were as-
sessed using temporal decomposition hazard methodology
Table 1 Baseline Characteristics and Major Bleeding Outcomes After HMII Implantation
Baseline Characteristic
Cleveland
Clinic Cohort
(n ¼ 139)
Extended MCS
BTT Cohort
(n ¼ 281) (1)
Post-FDA Approval
BTT Cohort
(n ¼ 169) (2)
HMII DT
Randomized Trial
(n ¼ 134) (3)
HMII BTT
UMN Cohort
(n ¼ 102) (4)
Study enrollment dates October 2004 to
June 2010
March 2005 to
April 2008
April 2008 to
August 2008
March 2005 to
May 2007
June 2005 to
June 2010
Age (yrs) 54  13.5 50  13 d 62  12 52  13
Female 31 (22) 67 (24) 38 (17) 26 (19) 26 (26)
Race
White 108 (78) 194 (69) 125 (74) d d
Black 27 (19) 61 (22) 29 (17) d d
Cardiomyopathy type
Ischemic 65 (47) 121 (43) d 88 (66) 58 (57)
Dilated/nonischemic 59 (42) d d d 36 (35)
Hypertrophic 11 (8) d d d d
Valvular 4 (3) d d d d
INTERMACS score
1: Critical ADHF cardiogenic shock 46 (33) d 41 (24) d 17 (18)
2: Progressive ADHF decline 30 (22) d 63 (37) d 13 (13)
3: Inotrope dependent 28 (20) d 33 (20) d 13 (13)
4: Recurrent ADHF failure 33 (24) d 21 (12) d 16 (17)
5: Exertional CHF tolerant 2 (1.4) d d d 25 (26)
Intent for HMII
Bridge to transplant 55 (40) 281 (100) 169 (100) d 102 (100)
Bridge to decision 53 (38) d d d d
Destination therapy 31 (22) d d 134 (100) d
Pre-operative cardiac support
Inotropes 85 (61) 252 (90) 136 (80) 103 (77) d
Intra-aortic balloon pump 44 (32) 126 (45) 15 (10) 30 (22) d
Extracorporeal membrane oxygenation 14 (10) d d d d
Post-HMII bleeding events
Mean follow-up duration (days) 489 155 306 621 327
Cumulative bleeding occurrence 81 (58) 148 (53)* 75 (44)y 108 (81)z 35 (34)x
Cumulative event rate (n/patient-yrs) 1.14 1.67 1.44 1.66 d
Cumulative follow-up (patient-yrs) 171 182 142 211 138
Values are mean  SD or n (%). Results are compared across the presented and previously reported BTT and DT studies. The column headings indicate the number of HMII recipients included in each study.
Unavailable or incomplete data are indicated by a dash. *Bleeding requiring 2 U of packed red blood cells. yBleeding per INTERMACS criteria. zBleeding requiring packed red blood cells. xGastrointestinal
bleeding and mediastinal bleeding requiring reoperation.
ADHF ¼ acute decompensated heart failure; BTT ¼ bridge to transplant; CHF ¼ congestive heart failure; DT ¼ destination therapy; FDA ¼ Food and Drug Administration; HMII ¼ HeartMate II;
INTERMACS ¼ Interagency Registry for Mechanically Assisted Circulatory Support; MCS ¼ mechanical circulatory support; UMN = University of Minnesota.
JACC Vol. 62, No. 23, 2013 Bunte et al.
December 10, 2013:2188–96 Major Bleeding During HeartMate II Support
2191to ﬁt data by nonlinear mixed regression (SAS PROC
NLMIXED). This technique permitted the assessment of
speciﬁc risk factors resolved within 2 hazard phases: an
early peaking (e.g., initial hospitalization) phase and late
increasing (e.g., post-discharge) phase. Variable coefﬁcients
were then simultaneously modeled in early and late hazard
phases using a log-linear function. Variables with more than
25% of values missing were excluded. For suitable variables
with missing data, values were imputed 5-fold using the
SAS PROC MI procedure and Markov Chain Monte
Carlo technique (15,16). Bootstrap bagging was used to
test variables for reliability and then select those for multi-
variable models (17). Variables were retained if they
demonstrated 50% reliability at an alpha level 0.07 among
500 bootstrapped samples with automated stepwise
selection.
Repeated post-operative INR measurements were an-
alyzed longitudinally and modeled as time-varying covariatesfor effect on primary bleeding outcomes. Univariate and
multivariable regression analyses were performed using the
last INR measurement that preceded a bleed. See the Online
Appendix for additional details on available INR records and
how INR was used in this subanalysis.
The effect of post-surgical bleeding on mortality was
analyzed using Nelson’s cumulative event function to obtain
nonparametric survival estimates. Parametric estimates were
obtained from a multiphase hazard function model of time-
related events. Bootstrap bagging was again used to select
variables for multivariable models (17). Post-operative
bleeding was treated as a time-varying covariate, creating
a modulated renewal process to determine the instantaneous
risk of death after surgery. Survival analysis among patients
treated with BTT was performed with the Kaplan-Meier
estimator. Destination therapy patients were excluded from
survival analysis to avoid confounding of bleeding effect
among this inherently higher risk cohort.
Table 2
Bleeding Subtypes and Recurrent Major Bleeding
Events After HeartMate II Implantation
Bleeding event type
Thoracic and mediastinal 61 (42.1)
Anemia of undetermined source 29 (20.0)
Lower gastrointestinal bleeding 18 (12.4)
Upper gastrointestinal bleeding 12 (8.3)
Central nervous system 10 (6.9)
Epistaxis 5 (3.4)
Femoral artery access site bleeding 3 (2.1)
Pulmonary hemorrhage 2 (1.4)
Non cardiac post-surgical bleeding 2 (1.4)
Disseminated intravascular coagulation 1 (0.7)
Menorrhagia 1 (0.7)
Hemorrhagic hepatic cyst 1 (0.7)
Repeated bleeding events
First bleed 81 (55.9)
Second bleed 38 (26.2)
Third bleed 21 (14.5)
Fourth bleed 4 (2.8)
Fifth bleed 1 (0.7)
Values are n (%). Overall bleeding events (n ¼ 145) among 81 of 139 (58%) HeartMate II recipients
are listed by number and percentage of total events. Repeated events are similarly presented.
Figure 2
Incident Major Bleeding After
HeartMate II Implantation
The occurrence of major bleeding rose rapidly after surgery and then leveled off on
long-term follow-up. The solid line represents a parametric estimate enclosed
within 68% conﬁdence limits (dashed lines). Vertical lines represent asymmetric
68% conﬁdence limits, and the numbers in parentheses indicate patients at risk
for subsequent events.
Table 3
Factors Related to Major Bleeding After
HMII Implantation
Factor Coefﬁcient  SE p Value R*
Early hazard phase
Total bilirubin level 0.79  0.39 0.04 75
HMII implant year 8.96  2.36 0.0002 99
Cardiopulmonary bypass time 0.73  0.21 0.0003 67
Number of previous combined
bleeds
(renewal variable)
1.21  0.28 <0.0001 100
Late hazard phase
Total bilirubin level 0.71  0.023 0.002 60
Pulmonary artery systolic
pressure
1.86  0.86 0.03 52
Risk factors for combined bleeding in the early (i.e., index hospitalization) hazard phase included
low total bilirubin level, earlier year of HMII implantation, and prolonged time on cardiopulmonary
bypass. Using a process of modulated renewal, the number of prior bleeding events was associated
with a lower risk of subsequent bleeding. In the late (i.e., post-hospitalization) hazard phase,
elevated total bilirubin level and increased pulmonary artery pressure were incremental factors for
bleeding. Covariates are listed with corresponding coefﬁcient with SE. *R represents reliability.
Percent of times factor appeared in 500 bootstrapped analyses.
HMII ¼ HeartMate II.
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A complete list of baseline characteristics is shown in the
Online Appendix. For comparison, several baseline charac-
teristics from our cohort are compared with those of
other pivotal HMII studies, along with respective bleeding
deﬁnitions and event rates (Table 1). Forty percent of our
cohort received HMII support as BTT, 38% as bridge to
candidacy, and 22% as destination therapy. Most patients
had a pre-operative INTERMACS score of 1 (33%) or
2 (22%). The median follow-up time on HMII support
was 489 days (interquartile range: 350 to 715 days) for
a total of 170.9 patient-years of follow-up. Ten percent
of survivors had follow-up >949 days (2.6 years). Among
our cohort, 42% had no major bleeding events.
Occurrence and risk of bleeding events. Among the
139 HMII recipients, 81 patients (58%) had 145 major
bleeding events (Table 2). The cumulative incidence of
bleeding peaked within the ﬁrst 3 post-operative months
(Fig. 2). Most patients with bleeding experienced a single
event (56%). A minority of patients experienced repeated
bleeding occurrences, which included second, third, fourth,
and a single ﬁfth major bleed (Table 2). After adjusting for
other factors, a ﬁrst bleed did not predict subsequent bleeding
events in a multivariable model. Moreover, after a ﬁrst bleed,
the probability of subsequent bleeding in the early hazard
phase decreased (Table 3). When stratiﬁed into eras of
implantation, including early-term (2004 to 2006), midterm
(2007 to 2008), and late-term (2009 to 2010), the cumulative
incidence of major bleeding decreased with each subsequent
era (Fig. 3).
Incremental risk factors for overall bleeding were resolved
into 2 hazard phases. In the early (i.e., index hospitalization)hazard phase, low values of pre-operative total bilirubin,
increased cardiopulmonary bypass time, and early HMII
implant year were associated with bleeding (Table 3). In the
late (i.e., post-discharge) hazard phase, elevated pre-
operative total bilirubin value and increased pre-operative
pulmonary artery systolic pressure were independently
predictive of bleeding events. Having a prior bleed was
associated with a lower risk of future bleeds in the early
hazard phase. Although incident major bleeding oc-
curred most frequently among patients with the highest
pre-operative INTERMACS acuity score, overall the
Figure 3 Major Bleeding by Era of HeartMate II Implantation
The cumulative incidence of overall bleeding complications demonstrates a graded
reduction when divided into early-term (2004 to 2006), midterm (2007 to 2008),
and late-term (2009 to 2010) implantation. The numbers in parentheses indicate
patients at risk for subsequent events.
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2193INTERMACS proﬁle was not a consistent predictor of
bleeding (Online Appendix).
Thoracic and mediastinal bleeding predominated all
subtypes of bleeding (Fig. 4) and drove the high overall
risk of early post-operative bleeding within the ﬁrst 2 post-
operative weeks (Fig. 5). Thoracic and mediastinal bleeding
developed at a median of 1 day from surgery (range: 0 to 89
days) and accounted for 42% of all major bleeds. The next
most common subtype of bleeding was of GI sources,
accounting for 21% of events. For analysis of GI bleeding,
upper and lower bleed events were combined into a singleFigure 4 Bleeding Incidence by Subtype
Overall, thoracic bleeding events predominated the early incidence of bleeding,
whereas gastrointestinal (GI) bleeding and central nervous system (CNS) hemor-
rhage increased on long-term follow-up. Vertical lines represent asymmetric 68%
conﬁdence limits, and the numbers in parentheses indicate patients at risk for
subsequent events.category. GI bleeds occurred at a median of 33 days from
surgery (range: 1 to 530 days), with the greatest risk within
the ﬁrst post-operative month (Fig. 5). Recurrent GI bleeds
were common; one-third were repeat events.
AUS events occurred early and were also common,
accounting for 20% of all bleeds. AUS events mirrored the
temporal pattern of incident thoracic bleeds, with themajority
of events occurring close to surgery (Fig. 4). INTERMACS-
deﬁned hemolytic events (plasma-free hemoglobin level
>40 mg/dl in association with clinical signs associated with
hemolysis occurring in the ﬁrst 72 h post-implantation) were
not observed among those categorized as AUS. A single
patient in our cohort experienced INTERMACS-deﬁned
hemolysis that required transfusion; this anemia event was
not included in the analysis of AUS bleeding.
Coagulation status and post-implantation hemostasis. We
considered the last measurement of INR before the event
for analysis. In unadjusted models, higher INR levels
predicted combined bleeding events as well as thoracic
and GI bleeding subtypes. After adjusting for other
variables, INR was no longer predictive of a ﬁrst or
recurrent bleed by multivariable analysis (Online
Appendix). Over the ﬁrst year, the mean INR for ﬁrst-
time bleeding events was not signiﬁcantly different from
that of patients without these complications (Fig. 6).
Mortality associated with post-implantation bleeding.
Parametric survival estimates among BTT and bridge-
to-candidacy HMII recipients at 1, 6, 12, and 24 months
of HMII support were 95%, 85%, 74%, and 54%, respec-
tively (Online Appendix). The risk of death in the overall
cohort was examined in a multiphase multivariable model of
bootstrapped covariates, including time-related bleeding
variables. The number of bleeding events increased the risk
of death in the early hazard phase (Table 4). In the late
hazard phase, elevated creatinine level and prolonged dura-
tion from surgery to bleeding were reliable, independent
risk factors for death (Table 4). Although a reliable variable
for modeling, the number of recurrent bleeding events did
not provide independent, incremental prediction of late-
term mortality. However, when analyzed over time, those
who experienced a second bleed demonstrated a rapid early
and sustained reduction in survival relative to those without
bleeding or a ﬁrst-time bleed (Fig. 7).
Discussion
This study highlights the complex interplay of bleeding
complications early after HMII implantation, predominated
by early thoracic and mediastinal, GI, and AUS events.
We assessed the inﬂuence of pre-operative variables on
bleeding events as have others, but we also incorporated the
dynamic factors of timing, type of bleeding, and anti-
coagulation status on subsequent events. To our knowledge,
this is the ﬁrst study to resolve the risk of post-HMII
bleeding into 2 clinically relevant phases. In doing so, we
uniquely demonstrate how time-sensitive factors relate to
Figure 5 Risk of Bleeding After HeartMate II Implantation
The instantaneous risk of overall bleeding (black line) was highest in the ﬁrst
several days after transplantation and promptly tapered. The inset demonstrates
the risk proﬁles of thoracic bleeding and gastrointestinal bleeding.
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account of major bleeding requiring transfusion after HMII
implantation.
A detailed classiﬁcation of bleeding by subtype
demonstrates important relations, including that of early
thoracic, GI, and AUS events as well as late GI and central
nervous system bleeds (Fig. 4). AUS events likely high-
light limitations of endoscopic, noninvasive, and invasive
diagnostic testing for post-HMII anemia as well as our
retrospective analysis of bleeding events. Although inclu-
sion of AUS events adds complexity to an alreadyFigure 6
Mean INR Among HeartMate II Recipients
With and Without Recurrent Bleeding
Overall, the mean international normalized ratio (INR) of patients without bleeding
(red line) was not signiﬁcantly different than among those with a ﬁrst bleed
(green line) over several months of follow-up.heterogeneous literature on bleeding, AUS importantly
accounts for a signiﬁcant portion of transfusions when
a deﬁnitive source of blood loss is not apparent. Future
prospective studies speciﬁcally targeting AUS may provide
valuable insights into reducing transfusion events,
regardless of their cause.
As anticoagulation protocols have evolved and technical
challenges of implantation have been overcome, the inci-
dence of bleeding during HMII support has decreased
substantially. The risk of bleeding events declined over
implantation eras, with the cumulative incidence of
bleeding reduced by one-half between the 2007 to 2008 and
2009 to 2010 cohorts (Fig. 3). Although no single factor
clearly accounted for these changes, the declining trend in
bleeding complications is rather likely a reﬂection of several
concurrent improvements to patient selection, operative
techniques, and early post-operative anticoagulation proto-
cols, among other factors. Nevertheless, the pattern of early
post-operative bleeding remained consistent in our cohort
over implantation eras, characterized by a prompt early rise
and precipitous fall shortly after HMII implantation.
Having a history of post-HMII bleeding seemed to
reduce the risk of future early-phase but not necessarily late-
phase bleeds (Table 3). The mean INR among those who
had prior bleeds tended to trend lower than among those
with no or ﬁrst-time bleeds (Fig. 6), possibly representing
increased clinical vigilance and reduction in anticoagulation
in response to bleeding. Importantly, early, but not late,
bleeding complications tended to increase the risk of death
in our cohort (Table 4). With the association of transfusion
and mortality established (6), our results emphasize the
detrimental role of bleeding. Perhaps through an association
with early transfusion, these results also focus that risk in the
days after surgery. Further prospective analysis of this
association between transfusions and outcomes among
HMII recipients may prompt strategies to avoid anemia and
post-operative transfusions.
Multivariable predictors of bleeding in our cohort
included low total bilirubin level and severe pulmonary
hypertension. Our ﬁnding of a low bilirubin level associated
with early bleeding risk seems contradictory to other reports
(18–20). Regardless, additional studies are needed to further
characterize links between post-HMII bleeding risk, hepatic
dysfunction (18), and right ventricular failure (19,21), as has
been suggested elsewhere. Considerable interest has focused
on syndromes of platelet dysfunction potentially unique to
the HMII device, including an acquired type IIA von
Willebrand syndrome (22–26). Additional study of blood
product use, platelet aggregometry, and thromboelastog-
raphy may prove useful in perioperative bleeding risk strat-
iﬁcation. Similar to scores used to predict post-HMII
survival (27,28), an individualized score to predict bleeding
could offer tailored post-operative anticoagulation that may
limit bleeding.
Thoracic and mediastinal bleeding predominated within
the ﬁrst post-operative week and overall accounted for
Table 4
Factors Related to Death Incorporating
Timing and Incidence of Major Bleeding After
HeartMate II Implantation
Factor Coefﬁcient  SE p Value R*
Early hazard phase
Number of bleeding events
(modulated renewal)
1.19  0.36 0.001 93
Time to bleeding event 2.71  1.96 0.2 93
Destination therapy 0.22  0.76 0.8 28
Late hazard phase
Number of bleeding events
(modulated renewal)
1.17  0.73 0.1 92
Time to bleeding event 3.48  1.19 0.003 92
High creatinine level 1.04  0.35 0.003 62
Destination therapy 0.81  0.57 0.1 33
In a bootstrapped multivariable model, the number of bleeding events was a reliable incremental
risk factor for death in the early (i.e., index hospitalization) hazard phase. In the late (i.e., post-
hospitalization) hazard phase, an elevated creatinine level and delayed time to bleeding event
were reliable incremental risk factors for death. Destination therapy was not included in the ﬁnal
multivariable model due to insufﬁcient reliability (<50%) in both the early and late hazard phases.
Covariates are listed with corresponding coefﬁcient with SE. *R represents reliability. Percent of
times factor appeared in 500 bootstrapped analyses.
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219542% of all bleeding events. Reported rates of thoracic
bleeding in this analysis are considerably higher than the
results of previously reported studies, including a 31% rate
of reoperation for bleeding in an early experience (25). This
noteworthy difference is a result of our goal of high sensi-
tivity for bleeding or anemias that led to transfusion. We
accounted for any source of thoracic bleeding, regardless
of whether the patient returned to the operating room,
as long as a thoracic source could be identiﬁed and trans-
fusion criteria were met. Certainly, the wide scope of our
deﬁnition of thoracic bleeding loses speciﬁcity when
compared with other studies. All the same, with the use of
an inclusive, transfusion-sensitive deﬁnition, we found thatFigure 7
Estimated Survival After HeartMate II Implantation
by Bleeding Status
Survival among those with no bleeding or a ﬁrst bleed was greater than in those
who experienced a second bleeding event. Survival declined rapidly early after
each bleed (early hazard phase), although it leveled off on post-discharge follow-up
(late hazard phase) among those with ﬁrst-time bleeds.bleeding requiring transfusion was very common shortly
after surgery.
Study limitations. The results of this observational analysis
complement existing data with additional detail on post-
HMII bleeding complications, although important limita-
tions exist. This study spanned several years of HMII
implantation at a single center, and so the ability to generalize
these results may be limited. During 7 years of HMII
implantation, many changes in the clinical management of
device recipients occurred, which provide heterogeneity to
our analysis. Furthermore, we did not perform subgroup
analysis of INTERMACS score by implantation era. Such
an analysis may have conﬁrmed suppositions of reduced
bleeding among lower acuity recipients while other era-related
factors, such as anticoagulation protocols or implantation
techniques, were also changing. Although we attempted to
use comprehensive statistical modeling, there are likely
inﬂuential factors for bleeding for which our analysis did not
account. We attempted to use INTERMACS deﬁnitions for
adverse events with limited manipulation. A retrospective
analysis of bleeding events likely contributed to increased
AUS categorization.Conclusions
Bleeding complications peak in the early post-operative
course after HMII, demonstrating a complex interplay
of bleeding subtypes shortly after surgery. Although the
observed decline in bleeding event rates over time is
encouraging, bleeding and anemia requiring transfusion
are common and associated with increased risk of post-
surgical mortality. The additional inﬂuence of trans-
fusions and alterations of platelet function during HMII
support, particularly early after surgery, merit additional
investigation. To this end, axial ﬂow ventricular assist
device technology will more safely and effectively fulﬁll its
role among a growing number of patients with advanced
heart failure.Reprint requests and correspondence: Dr. Maria M. Mountis,
Robert and Suzanne Tomsich Department of Cardiovascular
Medicine, J3-4, Heart and Vascular Institute, Cleveland Clinic,
9500 Euclid Avenue, Cleveland, Ohio 44195. E-mail: mountim@
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APPENDIX
For expanded information on Methods and Results, please see the online
version of this article.
